EP0197059A1 - Peptide pharmacologiquement actif - Google Patents

Peptide pharmacologiquement actif

Info

Publication number
EP0197059A1
EP0197059A1 EP85904607A EP85904607A EP0197059A1 EP 0197059 A1 EP0197059 A1 EP 0197059A1 EP 85904607 A EP85904607 A EP 85904607A EP 85904607 A EP85904607 A EP 85904607A EP 0197059 A1 EP0197059 A1 EP 0197059A1
Authority
EP
European Patent Office
Prior art keywords
tyr
phe
val
pro
pharmacologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP85904607A
Other languages
German (de)
English (en)
Inventor
Victor Dr. Med. Dipl.-Chem. Brantl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0197059A1 publication Critical patent/EP0197059A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the invention relates to pharmacologically active peptides, in particular having an opiate-like effect.
  • the object of the invention is to create new, not yet described peptides which in particular have an oplate-like effect.
  • Tyr is the same the amino acid tyrosine
  • Phe is the amino acid phenylalanine
  • Val is the amino acid valine
  • Pro is the amino acid proline
  • A is L-proline or any D-amino acid
  • B, C and D can be any amino acid of the D or L form.
  • T stands for OH, OR, NH 2 or NHNHR ', where R may have the following meaning: Substit.
  • C 1-16 acyl optionally substituted by OH, NH 2 , C 1-4 alkoxy or halogen, aromatic acyl, optionally substituted by OH, NH 2 , halogen or C 1-4 alkoxy; linear, branched or cyclic C 3-11 aliphatic urethane and their pharmaceutically acceptable salts.
  • the D-amino acid at position 2 of the peptide brings about a significant increase in the opiate-like effect, combined with a stabilization of the peptides against degradation by proteolytic enzymes in the blood.
  • the peptides are characterized in that a) the N-terminal L-tyrosine of the general formula:
  • R 3 for hydrogen or an alkyl group with 1 to C atoms
  • R 4 for hydrogen or together with R 3 for an ethylene bridge
  • R 5 for hydrogen, an alkyl group with 1 to 4 C atoms or an R 6 CO group
  • R 6 is a saturated or unsaturated, straight-chain or branched alkyl radical having 1 to 17 carbon atoms, a phenyl radical or a phenylalkyl radical having 7 to
  • R 7 represents hydrogen or alkyl having 1 to 4 carbon atoms
  • R 8 for hydrogen, fluorine, chlorine, bromine, nitro, alkyl
  • R 9 hydrogen, a hydroxyl group, an alkyl or alkoxy group with 1 or 4 carbon atoms - An alkyl or alkoxy group having 1 to 4 carbon atoms is bonded to the nitrogen
  • the amino acids proline, phenylalanine and B, C and D are present as dehydroamino acids.
  • the phenylalanine is present in the 3rd form in the 3rd amino acid position of the peptide (calculated from the N-terminal end of the peptide) in the D form.
  • the same as above The peptides have a stabilizing effect when the valine is in the 4th amino acid position in the D form.
  • the peptides according to the invention can have strong effects on the central nervous system.
  • This effect can e.g. after intracerebroventricular administration of the peptides to rats.
  • the animals show a catatonic state (body rigidity), such as is comparable to neuroleptic effects.
  • the peptides according to the invention can trigger endocrine effects.
  • this can be a growth hormone level increase (GH) or an insulin-releasing effect.
  • GH growth hormone level increase
  • the peptides according to the invention trigger opiate-like effects in vivo and in vitro.
  • peptides produced according to the invention can trigger hypotensive effects in vivo.
  • Peptides of the following structure are particularly advantageous: Tyr-Pro-Phe-Val-OH
  • the peptides according to the invention can be used as antigens to generate antibodies in the mammalian organism.
  • the peptide is coupled to the macromolecule in the usual way with carbodlimide and injected into the back and the abdominal skin of rabbits.
  • the antibodies obtained in this way can then be used to determine the peptides according to the invention in body tissues and fluids.
  • the peptides according to the invention and / or their derivatives and / or their salts can be contained in human and veterinary medicinal products.
  • peptides can also be used to promote growth as animal feed additives.
  • the synthetic method used uses benzyloxycarbonyl-protected amino acids as mixed anhydrides (Lottsspeich et al., Hoppe-Seyler's Z. Physiol. Chem., 1835-1839, 1980).
  • the amino component at -15 ° C. or lower in dimethylformamide (DMF) with a 0.5 molar excess of mixed anhydride of a Z-amino acid isobutylcarboxylic acid (Z- serving as a protective group and representing an N-benzyloxycarbonyl radical) for 2-4 hours implemented. After the 2-4 hour coupling, the excess anhydride is destroyed.
  • the pH of the reaction product is then adjusted to 8 with aqueous, saturated KHCO 3 solution at 0 ° C. and stirred at 0 ° C. for 30 minutes.
  • the peptides are extracted with ethyl acetate.
  • the ethyl acetate / peptide mixture is washed 3 times with NaCl / water, 3 times with water and evaporated.
  • the peptide thus obtained, which still bears the protective group Z, is then hydrogenated in methanol.
  • 100-500 mg Pd / activated carbon are added as catalyst per mmol peptide.
  • the elimination of CO 2 is controlled with Ba (OH) 2 solution.
  • the catalyst is then filtered off (paper filter), washed extensively with water and the filtrate evaporated on an ation evaporator.
  • the desired deblocked peptide is contained in the residue.
  • stage II / stage 2 implementation of the Anhydrids of stage Il / la with the amino component of stage Il / la with the amino component of stage Il / lb.
  • the Z-L-Phe mixture is reacted in a total of 40 ml DMF at -15 ° C with the amino component II./lb to the Z-L-Phe-L-ValOMet.
  • the processing takes place as already described under 1/2 and 1/3.
  • Tyr-Pro-Phe-Val-Glu- ⁇ , ⁇ -diMet are then either directly via column chromatography
  • Tyr-Pro-Phe-Val-OH Tyr-Pro-Phe-Val-Glu-OH was then examined for pharmacological effects.
  • the preparation of the other peptides according to the invention was carried out on the same catfish as already described above, the Z-amino acid derivatives (for example ZD-alanine or ZD-valine instead of the ZL-proline described above) or amino acid esters (proline methyl ester, isoleucine) corresponding to the desired sequence OMet, Tyrosin-OMet and Phenylalanin-OMet) can be used.
  • the peptide esters can then be subjected to ammonolysis in the usual way for the purpose of C-terminal amidation.
  • Example Pharmacological effects of two peptides according to the invention (Tyr-Pro-Phe-Val-OH and Tyr-Pro-Phe-Pro-Val-GluOH).
  • the two substances show specific opiate-like effects on the electrically stimulated plexus myentericus / longitudinal muscle preparation of the guinea pig ileum (GPI), method according to Schulz and Goldste ⁇ n, J. Pharmacol .. Exptl. Ther. 183, 400, 1972.
  • GPI guinea pig ileum
  • the numbers indicate the concentration ( ⁇ M) which is necessary to inhibit the electrically induced contraction of the guinea pig intestine preparation (GPI) by 50% (IC 50 value).
  • the numbers are mean values from 4 determinations; the standard deviation from the mean values is less than 12%.
  • the inhibitions of the GPI are with the speci see opioid antagonists naloxone can be canceled or blocked during pretreatment.
  • the corresponding D-Ala 2 compounds show even stronger opiate-like effects on the GPI preparation. Opiate-like effects can also be observed in rats after intracerebroventricular injection. Hieibei is operated as described by Brantl et al., Life Sciences, 28, 1903-1909, 1981.
  • An effective analgesic dose proved to be 350 to 500 ⁇ g of the above peptides; the analgesic effect can be reversed with naloxone 10 mg per kg body weight (intraperitoneally) or blocked with pretreatment with naloxone.

Abstract

Des nouveaux peptides pharmacologiquement actifs ont la formule générale (I), dans laquelle Tyr est égal à l'acide aminé tyrosine, Phe est égal à l'acide aminé phénylalanine, Val est égal à l'acide aminé valine, Pro est égal à l'acide aminé proline, A est égal à L-proline ou à un acide aminé D quelconque; B, C et D peuvent être n'importe quel acide aminé de forme D ou L. Ces compositions sont utiles dans le traitement de maladies.
EP85904607A 1984-09-28 1985-09-23 Peptide pharmacologiquement actif Withdrawn EP0197059A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3435727 1984-09-28
DE19843435727 DE3435727A1 (de) 1984-09-28 1984-09-28 Pharmakologisch aktive peptide

Publications (1)

Publication Number Publication Date
EP0197059A1 true EP0197059A1 (fr) 1986-10-15

Family

ID=6246668

Family Applications (2)

Application Number Title Priority Date Filing Date
EP85904607A Withdrawn EP0197059A1 (fr) 1984-09-28 1985-09-23 Peptide pharmacologiquement actif
EP85112028A Expired EP0176070B1 (fr) 1984-09-28 1985-09-23 Peptide à activité pharmacologique

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP85112028A Expired EP0176070B1 (fr) 1984-09-28 1985-09-23 Peptide à activité pharmacologique

Country Status (4)

Country Link
EP (2) EP0197059A1 (fr)
AT (1) ATE42308T1 (fr)
DE (2) DE3435727A1 (fr)
WO (1) WO1986002079A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3514587A1 (de) * 1985-04-23 1986-10-30 Victor Dipl.-Chem. Dr.med. 6200 Wiesbaden Brantl Pharmakologisch aktive peptide
ZA873796B (en) * 1986-06-06 1987-12-07 F. Hoffmann-La Roche & Co. Aktiengesellschaft Peptides
ZA883929B (en) * 1987-06-22 1990-02-28 Hoffmann La Roche Cholecystokinin analogs for controlling appetite
GB8800600D0 (en) * 1988-01-12 1988-02-10 Univ Manchester Increasing efficiency of animal performance
SG64368A1 (en) * 1988-06-30 1999-04-27 Astra Ab Dermorphin analogs their methods of preparation pharmaceutical compositions and methods of therapeutic treatment using the same
US5602100A (en) * 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
US6184208B1 (en) 1994-06-29 2001-02-06 Immunotech Developments Inc. Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
RU2067000C1 (ru) * 1994-06-29 1996-09-27 Владислав Исакович Дейгин Пептид и способ его получения
CA2698852A1 (fr) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Utilisation d'un peptide comme agent therapeutique
WO2014020209A1 (fr) * 2012-07-30 2014-02-06 Consejo Superior De Investigaciones Científicas (Csic) Utilisation d'hydrolysats de protéines lactées comme protecteurs au niveau gastro-intestinal

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2921216A1 (de) * 1979-05-25 1980-12-04 Teschemacher Hansjoerg Pharmakologisch aktive peptide
EP0053029A1 (fr) * 1980-11-24 1982-06-02 Peninsula Laboratories Incorporated Peptides n'étant pas du genre encéphaline, leur préparation, compositions les contenant et leur usage médical et vétérinaire

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8602079A1 *

Also Published As

Publication number Publication date
EP0176070A1 (fr) 1986-04-02
ATE42308T1 (de) 1989-05-15
EP0176070B1 (fr) 1989-04-19
WO1986002079A1 (fr) 1986-04-10
DE3569541D1 (en) 1989-05-24
DE3435727A1 (de) 1986-04-10

Similar Documents

Publication Publication Date Title
DE2616399A1 (de) Polypeptid und verfahren zu seiner herstellung
JPH0811746B2 (ja) 新規ペプチド化合物
EP0176070B1 (fr) Peptide à activité pharmacologique
DE2714141A1 (de) Dipeptid-analoge und verfahren zu ihrer herstellung
EP0019829B1 (fr) Peptides à activité pharmacologique et leurs compositions
CH676425A5 (fr)
EP0292729B1 (fr) Procédé de synthèse de peptides en phase solide
DE2730549A1 (de) Peptidderivate und deren herstellung
DE2936099A1 (de) Pharmakologisch aktive peptide
CH615904A5 (en) Process for the preparation of L-leucine-13-motilin
DE2112553C3 (de) 1 -alpha-Aminolsobuttersäurecorticotropinpeptide, deren Derivate, Säureadditionssalze und Komplexe sowie Arzneipräparate
DE2408324A1 (de) Tripeptide und verfahren zu ihrer herstellung
EP0199331B1 (fr) Peptides à activité pharmaceutique
EP0137339B1 (fr) Peptides à activité pharmacologique
EP0248231B1 (fr) Peptides à activité pharmacologique
DE3340208A1 (de) Neue biologisch aktive peptide, verfahren zu deren herstellung und veterinaerpraeparate, welche diese enthalten
EP0320785A2 (fr) Peptides avec une activité influençant l'hypophyse des mammifères
EP0095557B1 (fr) Polypeptides avec activité antagoniste contre la substance P, procédé pour leur préparation, leur utilisation et procédé pour la purification de polypeptides
DE3047596A1 (de) Pharmakologisch aktive dipeptide
JPS6344595A (ja) 薬理的に活性のあるペプチツド
DE2534086A1 (de) Polypeptide mit acth-aehnlicher wirkung, ihre salze und komplexe, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE2727048C2 (de) 8-Norleucyl-ceruletide
DE3312399A1 (de) Biologisch aktive peptide und arzneimittel, welche diese enthalten
EP0516070B1 (fr) Dérivés de tryptophane protégés, procédé pour leur synthèse ainsi que leur emploi
WO1996024617A1 (fr) Desaminononapeptides, leur procede de preparation et leur utilisation pour preparer l'elcatonine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19860902